Dataset from A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

The primary objective of this study was to demonstrate whether, in addition to standard of
care, finerenone is superior to placebo in delaying the progression of kidney disease, as
measured by the composite endpoint of time to first occurrence of kidney failure, a sustained
decrease of estimated glomerular filtration rate (eGFR) ≥40% from baseline over at least 4
weeks, or renal death.